Alaa S Wahba, Hoda E Mohamad, Dina M Abo-Elmatty, Noha M Mesbah, Nehal S Wahba, Ahmed S El Azzazy, Amr T Sakr
{"title":"Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.","authors":"Alaa S Wahba, Hoda E Mohamad, Dina M Abo-Elmatty, Noha M Mesbah, Nehal S Wahba, Ahmed S El Azzazy, Amr T Sakr","doi":"10.1097/FBP.0000000000000835","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000835","url":null,"abstract":"<p><p>This study aimed to investigate and characterize Parkinson's-like behavioral, histological, and biochemical changes induced by feeding fructose (10% w/v) for 24 weeks in rats. Additionally, we aimed to evaluate the potential protective effect of dulaglutide and empagliflozin either individually or combined with pirfenidone on fructose-induced Parkinsonian features. Rats were given 10% w/v fructose solution for 24 weeks and cotreated for the last 4 weeks with either empagliflozin (30 mg/kg/day orally), dulaglutide (0.2 mg/kg/week subcutaneously), pirfenidone (100 mg/kg/day orally), or the combination of the latter with empagliflozin or dulaglutide at the same mentioned doses. Behavioral testing was done at the end of the study period, and brain tissue samples were taken at sacrifice. Fructose-fed rats showed aberrations in cognitive function and motor coordination constellated with loss of substantia nigra neurons, dopamine deficiency, and altered α-synuclein, LRRK2, and parkin expression. This was associated with insulin resistance, dyslipidemia, enhanced neuroinflammation, and apoptosis. All treatments ameliorated these perturbations with more pronounced effects observed in the combination groups. Current results revealed the neuroprotective potential of dulaglutide, empagliflozin, and pirfenidone against fructose-induced neurobehavioral alterations in rats with an additive effect observed with the combined therapy.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jyotpal Singh, Chase J Ellingson, M Abdullah Shafiq, Jane Alcorn, J Patrick Neary
{"title":"Cannabidiol and cognition: a literature review of human randomized controlled trials.","authors":"Jyotpal Singh, Chase J Ellingson, M Abdullah Shafiq, Jane Alcorn, J Patrick Neary","doi":"10.1097/FBP.0000000000000837","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000837","url":null,"abstract":"<p><p>Cannabidiol (CBD) is a phytocannabinoid without intoxicating properties. While CBD can improve neurophysiological functions and subjective symptoms, its effect on cognitive function remains unclear. We summarized the available randomized controlled trials investigating CBD administration and cognitive function. A review of the literature was conducted using the following keywords on PubMed/Medline: (cannabis OR cannabidiol OR cannabinoid OR CBD OR Δ9-tetrahydrocannabinol OR tetrahydrocannabinol) AND (neurology OR brain OR psychiatric OR neuroscience OR psychology OR cognition) AND (human) AND (randomized controlled trial OR RCT). The search yielded 1038 articles with 36 total included for this literature review. The articles included healthy participants, neurological disease, psychiatric disease, psychosis, paranoia, schizophrenia, and drug-use disorders. Studies with healthy participants included a variety of dosing strategies, suggesting an effect on cognitive function and sleep quality. In Parkinson's disease, 75-300 mg CBD resulted in mild improvements in daily life activities. Decreases in subjective anxiety were found in patients with psychiatric disease using CBD doses ranging from 300 to 400 mg. In patients with psychosis and paranoia, 600 mg CBD showed inconsistent results in cognitive function. In patients with schizophrenia, up to 1000 mg CBD per day had minimal effects on cognition. Finally, up to 800 mg CBD had minimal effects on cognitive function in patients with substance use disorders. The findings are limited by utilization of acute dosing, variations in CBD dose, and different routes of administration. Standardized dosing and CBD formulations are needed to assess its efficacy for improving cognition.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fan Zhang, Katherine L Nicholson, Keith L Shelton, Todd M Hillhouse, Herbert Y Meltzer, Joseph H Porter
{"title":"Role of serotonin 5HT2C receptors in the discriminative stimulus properties of lorcaserin in male C57BL/6 mice.","authors":"Fan Zhang, Katherine L Nicholson, Keith L Shelton, Todd M Hillhouse, Herbert Y Meltzer, Joseph H Porter","doi":"10.1097/FBP.0000000000000834","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000834","url":null,"abstract":"<p><p>The serotonin 2C receptor (5-HT2C) has been investigated as a potential therapeutic target for a variety of psychiatric disorders, as well as the treatment of obesity. A stumbling block in the development of these medications is identifying agonists with selectivity for 5-HT2C over 5-HT2A and 5-HT2B. Lorcaserin (Belviq) is a serotonin 5-HT2C agonist that was previously marketed as a weight-loss medication but was voluntarily withdrawn from the market because of a small, but an increased risk of serious side effects. The present study examined the discriminative stimulus properties of 2.0 mg/kg lorcaserin in a two-lever drug discrimination assay in male C57BL/6 mice using a fixed ratio 12 reinforcement schedule. A generalization curve with lorcaserin yielded an effective dose50 (ED50) = 0.56 mg/kg for substitution for the training dose. Lorcaserin produced a rapid onset, but short-acting (~60 min), discriminative stimulus, as full generalization was found as early as 15 min after drug administration. The 5-HT2C agonist meta-chlorophenylpiperazine fully substituted for lorcaserin with an ED50 = 0.31 mg/kg, and the 5-HT2C antagonist SB 242084 significantly blocked lorcaserin-lever responding (maximal effect at 0.25 mg/kg dose). Conversely, the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin did not substitute for lorcaserin. Thus, lorcaserin's discriminative stimulus appears to be mediated by agonist activity at 5HT2C receptors in C57BL/6 mice. These results demonstrated that lorcaserin drug discrimination can be trained in C57BL/6 mice and that it is a useful in-vivo assay for the future development of psychotherapeutic drugs for psychiatric disorders with selective 5-HT2C agonist activity.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-06-01Epub Date: 2024-12-16DOI: 10.1097/FBP.0000000000000809
Ronan Depoortère, Mariusz Papp, Piotr Gruca, Ewa Litwa, Magdalena Lason, Dominika Biała, Adrian Newman-Tancredi
{"title":"The antidepressant-like activity of ketamine in the rat chronic mild stress model requires activation of cortical 5-HT 1A receptors.","authors":"Ronan Depoortère, Mariusz Papp, Piotr Gruca, Ewa Litwa, Magdalena Lason, Dominika Biała, Adrian Newman-Tancredi","doi":"10.1097/FBP.0000000000000809","DOIUrl":"10.1097/FBP.0000000000000809","url":null,"abstract":"<p><p>Ketamine displays efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model. It rapidly reverses anhedonia (CMS-induced sucrose consumption deficit) and attenuates working memory deficit (novel object recognition: NOR) following both systemic (intraperitoneal, i.p.) administration or local administration in the prefrontal cortex (PFC). However, the receptor mechanisms underlying these effects remain to be clarified and may involve activation of serotonin 5-HT 1A receptors, as previously found in experiments using the forced swim test. The present study explored the contribution of PFC 5-HT 1A receptors in ketamine's RAAD activity in the CMS model. Ketamine (10 mg/kg i.p.) reversed CMS-induced sucrose consumption and working memory (NOR test) deficits. Notably, unilateral PFC microinjections of a 5-HT 1A receptor antagonist, WAY-100635 (2 µg), prevented the antidepressant-like and pro-cognitive activity of systemic ketamine on sucrose consumption and working memory deficits. These data indicate that the RAAD activity of ketamine in the rat CMS model requires activation of PFC 5-HT 1A receptors. They also reinforce the notion that drugs that directly activate PFC 5-HT 1A receptors could constitute an alternative to ketamine as a promising strategy to achieve RAAD effects, with additional benefits against cognitive deficits in depressed patients, but without ketamine's troublesome side-effects and requirements for in-patient supervision.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":"182-188"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-06-01Epub Date: 2025-05-07DOI: 10.1097/FBP.0000000000000827
Samuel Budniok
{"title":"The complexity of socially transmitted food preferences in rodents: a model for human epistemic trust?","authors":"Samuel Budniok","doi":"10.1097/FBP.0000000000000827","DOIUrl":"10.1097/FBP.0000000000000827","url":null,"abstract":"<p><p>Social safety learning refers to the process by which animals indirectly learn about the safety of novel stimuli. This process is critical when rodents decide what to eat since they lack the capacity to vomit, reducing their ability to expel ingested toxins. Consequently, rodents display neophobia when encountering novel food, but are more likely to eat the food when a conspecific signals its safety. This natural behavior is modeled using the social transmission of food preference (STFP) paradigm. Based on behavioral and neural insights into STFP, I argue in the current work that its acquisition may involve cognitive processes that extend beyond social safety learning. Specifically, I argue that STFP acquisition may parallel functional aspects of human epistemic trust. Epistemic trust refers to trust in communicated knowledge, enabling humans to learn from, adapt to, and respond to their (social) environment. This perspective could position the STFP paradigm as a valuable tool to investigate the neurobiology of cognitive processes that may be relevant to human epistemic trust. Given the importance of epistemic trust in therapeutic settings, understanding its neurobiology may have direct clinical implications.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 4","pages":"196-201"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-06-01Epub Date: 2025-05-07DOI: 10.1097/FBP.0000000000000829
Bart A Ellenbroek, Louk J M J Vanderschuren, Gernot Riedel
{"title":"In memory of Dr Emily Jutkiewicz, 1975-2024.","authors":"Bart A Ellenbroek, Louk J M J Vanderschuren, Gernot Riedel","doi":"10.1097/FBP.0000000000000829","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000829","url":null,"abstract":"","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 4","pages":"161-162"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-06-01Epub Date: 2025-04-01DOI: 10.1097/FBP.0000000000000826
Justyna K Hinchcliffe, Sarah A Stuart, Emma S J Robinson
{"title":"Investigating the effects of different herbal preparations, 5-hydroxytryptophan and involuntary exercise on affective bias modification in male Lister Hooded rats.","authors":"Justyna K Hinchcliffe, Sarah A Stuart, Emma S J Robinson","doi":"10.1097/FBP.0000000000000826","DOIUrl":"10.1097/FBP.0000000000000826","url":null,"abstract":"<p><p>Mood disorders are a prevalent global health concern with natural health products, including herbal supplements, an increasingly popular choice as an alternative or complementary therapy. Despite their widespread use, few studies have tested the clinical efficacy of natural health products or explored their underlying mechanisms in animal models. Modification of affective biases has been linked to mood in humans and animal models and may provide insights into potential antidepressant effects. In this study, we used a translational rodent model of affective bias modification to investigate the effects of five commonly used supplements: Hypericum perforatum , that is, St. John's Wort (SJW), Mucuna pruriens , Rhodiola rosea root extract, Valerian root extract and 5-hydroxytryptophan. Exercise is also thought to improve mood disorders, but clinical studies reveal mixed results therefore we also tested the effect of involuntary exercise on affective biases. In separate experiments, male Lister Hooded rats were acutely treated with SJW, Mucuna pruriens , Rhodiola rosea root extract, Valerian root extract and 5-hydroxytryptophan, or underwent an involuntary exercise manipulation. Our results showed a significant positive affective bias following treatment with SJW, whilst the involuntary exercise induced a negative affective bias in rats. No effects were found following the other acute treatments. These data suggest SJW has similar effects in terms of affective bias modification as conventional antidepressants. The negative affective bias observed with involuntary exercise suggests the animals experience a negative affective state and suggests exercise-based therapy may be less effective if the patient perceives this as involuntary.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":"189-195"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-06-01Epub Date: 2025-05-07DOI: 10.1097/FBP.0000000000000819
Emma S J Robinson
{"title":"Delivering a new generation of translational animal models for depression research.","authors":"Emma S J Robinson","doi":"10.1097/FBP.0000000000000819","DOIUrl":"10.1097/FBP.0000000000000819","url":null,"abstract":"<p><p>Early animal models of depression focused on developing methods that could predict treatment efficacy and were validated based on pharmacological responses to known antidepressants. As our understanding of major depressive disorder (MDD) and the pharmacology of antidepressants progressed, so did the need for better animal models. This need was met with the development of new disease models, such as the chronic mild stress model, and behavioural readouts such as the sucrose preference test, which more closely aligned with risk factors and symptoms seen in patients. These approaches have supported huge advances in the understanding of how stress affects the brain and impacts on reward-related behaviours. However, there remain significant challenges when trying to model complex psychiatric symptoms and disorders in non-human animals. In this perspective article, a brief history of animal models of depression and associated readouts is discussed with specific reference to the important contributions from Paul Willner. The main discussion then focuses on translational validity and approaches that may support delivering this objective. This is illustrated with the example of the affective bias test and reward learning assays, which have been developed to recapitulate in animals the neuropsychological impairments observed in MDD and modulation by antidepressants.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 4","pages":"175-181"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-06-01Epub Date: 2025-05-07DOI: 10.1097/FBP.0000000000000816
Kate M Witt, David N Harper, Bart A Ellenbroek
{"title":"A review on the validity of animal models for neuropsychiatric disorders: an exploration of anhedonia.","authors":"Kate M Witt, David N Harper, Bart A Ellenbroek","doi":"10.1097/FBP.0000000000000816","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000816","url":null,"abstract":"<p><p>Despite major advances in neuroscience, there has been limited progress in improving pharmacological treatment for neuropsychiatric disorders. Neuropsychiatric disorders are heterogeneous with variance in symptoms within disorders and partial overlap in symptoms between disorders, leading to symptoms that remain untreated. To improve treatment outcomes, neuroscience has shifted to examining the neurobiological mechanisms underlying individual components, or dysfunctions, across disorders. Anhedonia, a decreased capacity to experience pleasure from positive stimuli or rewards, is a prominent symptom associated with poor functional outcome across neuropsychiatric disorders. This article reflects on Professor Paul Willner's contributions to the field of behavioural neuroscience, specifically his promotion of validity in animal models of neuropsychiatric disorders. Research can build upon Willner's scholarship by continuing to refine and explore the validity of animal models as our understanding of neuropsychiatric disorders improves. To exemplify this, we discuss current understanding of the neurobiological basis and clinical presentation of the two domains of anhedonia: anticipation and consumption. We argue for the examination of anticipatory anhedonia and consummatory anhedonia within a single paradigm to improve understanding of these domains, aligning animal models to the clinical reality in humans.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 4","pages":"165-170"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}